23andMe R&D Day

Wade joined 23andMe in 2021 to lead the company’s investor relations efforts. He has extensive background in developing and implementing strategic investor relations programs within the biotech space. He has dedicated his professional efforts toward working with companies that are striving to translate science into benefits for people in need. Prior to joining 23andMe, Wade spent nine years at Ionis Pharmaceuticals, a leading company in RNA-targeted drug discovery and development, where he most recently served as Vice President of Investor Relations. During his time there, he was ranked as one of the top IR professionals three years in a row (2017–2019) by Institutional Investor magazine's 'All-American Executive Team' (Biotechnology) rankings. Prior to joining Ionis Pharmaceuticals, Wade also spent 13 years at Lexicon Pharmaceuticals, where he began as a Scientist and worked his way up to Associate Director of Bioinformatics in the Department of Functional Genomics. From there, he pivoted to lead Communications and Investor Relations for the company, a role in which he oversaw the implementation of a targeted program of IR activities. Wade holds a Bachelor of Science degree from Brigham Young University and Ph.D. and Master of Science degrees from the University of Michigan.

Anne co-founded 23andMe in 2006, three years after the first human genome was sequenced. Her goal was audacious: to help people access, understand, and benefit from the human genome and fundamentally change healthcare in the process. Prior to founding 23andMe, Anne spent a decade on Wall Street investing in healthcare and felt frustrated by a system built around monetizing illness instead of incentivizing prevention. She wanted to flip that model on its head and build a business that helps people prevent illness rather than profit from it. Anne focused on empowering people with direct access to genetic information so that they could use their data to make decisions that could lower their risks for disease. Under her leadership, 23andMe now provides the only personal genetic test with FDA authorization to deliver health information directly to consumers. From the beginning, Anne's goal and 23andMe’s mission has not wavered. Along with empowering consumers with health information, Anne wanted 23andMe to transform how research discoveries are made and revolutionize the development of treatments for disease. By inviting people to participate in research, 23andMe is able to crowdsource billions of data points resulting in the world’s largest resource for genetic research. This novel, web-based approach has already resulted in thousands of new genetic insights and allows 23andMe to rapidly recruit participants to multiple studies at once, reducing the time and resources needed to make discoveries and is integral to 23andMe’s mission of understanding and benefiting from the human genome This new approach to research also powers 23andMe’s therapeutics group, which is helping to translate this knowledge into new treatments for serious unmet medical needs. In line with this, 23andMe is now also using its unique model to speed recruitment for clinical trials. Anne is a pioneer in the direct-to-consumer DNA testing space and her vision and persistence have allowed 23andMe to provide people with unprecedented access to genetic information. Through its research platform, 23andMe has brought personalized medicine directly to millions of consumers. Anne graduated from Yale University with a BS in Biology.

Kenneth joined 23andMe in 2019 as Head of Therapeutics. He leads a dedicated discovery research and therapeutic development team that uses human genetic data to identify and pursue novel therapies for common and rare diseases. At Achaogen, Hillan served as Chief Executive Officer. He held progressively senior roles at Genentech-Roche including Senior Vice President and Head of Clinical Development and Product Development Strategy Asia-Pacific for Roche in Shanghai, China. He led the medical and scientific strategies for Genentech’s Immunology, Tissue Growth and Repair (ITGR) drug portfolio, and was responsible for numerous drug approvals. Hillan is a member of the board of directors at Zymeworks. He served on the board of directors at Achaogen, and at Relypsa until it was acquired by Galenica AG in 2016. He holds an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, U.K. He is a Fellow of the Royal College of Surgeons (FRCS, Glasg), and a Fellow of the Royal College of Pathologists (FRCPath). He has authored dozens of scientific publications and is a named inventor on almost 50 issued patents.

Adam joined 23andMe in 2015. Adam Auton is the Vice President of Human Genetics at 23andMe and is responsible for computational approaches to target discovery via statistical genetics and computational biology. Before joining 23andMe, Adam was an assistant professor at Albert Einstein College of Medicine, where his group developed algorithmic approaches for using large-scale genomic data to understand human population genetics. Adam earned his DPhil in statistics from Oxford University, before completing his post-doctoral training at the Wellcome Trust Centre for Human Genetics at Oxford, and Cornell University.

Adrian is a physician-scientist with 16 years of experience building and leading high performing drug development teams. He was motivated to join the Therapeutics group at 23andMe in 2019 by the potential to save as many lives as possible using the power of human genetics. At 23andMe, Adrian leads the Clinical Oncology and Neuroscience groups, in addition to several development functions (clinical operations, regulatory affairs, and toxicology) and the Oncology Discovery Team. During his tenure, 23andMe has advanced two immune-checkpoint inhibitors into clinical trials: anti-CD96 (in collaboration with GSK) and anti-CD200R1, a program that is wholly owned by 23andMe. Prior to 23andMe, Adrian was the Chief Medical Officer at Immune-Onc therapeutics, where he was responsible for the clinical development of checkpoint inhibitors for AML, and prior to that he was the Head of Early Development at Achaogen, a company focused on the threat of emerging infectious diseases. Earlier in his career, Adrian held numerous roles across research, early and late development at Genentech, and has contributed to multiple successful INDs/CTAs, an NDA and a 510k filing. He completed his medical and scientific training at the University of Leeds, where he received an MBChB(Hons) and PhD. Adrian then undertook a joint clinical and academic residency/fellowship at the University of Oxford, culminating in a faculty position and Fellowship of the Royal College of Pathologists (FRCPath). He has published over 60 peer reviewed scientific papers, including in the New England Journal of Medicine, Science Translational Medicine, Journal of Clinical Oncology, Lancet Oncology, Nature Reviews Cancer, Cancer Research, Clinical Cancer Research, Journal of the National Cancer Institute, and Blood.

Geoff joined 23andMe in 2010 and leads the Product R&D team, which is responsible for developing the next generation of data-driven products for 23andMe customers. This team works to keep 23andMe at the forefront of science and technology, driving the development of predictive models for human health and ancestry that utilize genetics, lifestyle, and environment. Previously, he was a venture capital intern at Burrill and Company. Geoff earned his Ph.D. in Cell Biology from the University of California, San Francisco where he was a National Science Foundation graduate research fellow.

Paul is the co-founder and former CEO of Lemonaid Health, now General Manager of the wider 23andMe consumer business which includes Lemonaid Health. Paul moved from the UK to the US in 2014 on a mission to bring about more convenient and affordable healthcare to everyone in America. In the UK Paul's entrepreneurial career started aged 17 where he founded his first company from the garage of his family home. Later Paul ran the UK's largest online pet retailer and became Head of Online for the one of the largest drugstore chains.

Joseph Arron earned an undergraduate degree from Princeton University, completed a combined MD-PhD degree at Cornell University Medical College and the Rockefeller University, and conducted postdoctoral studies at Stanford University School of Medicine. Dr. Arron joined Genentech in 2006, where his laboratory discovered pathogenic mechanisms and molecular bases for heterogeneity in respiratory disorders, enabling target and biomarker discovery for numerous investigational molecular therapies and over 75 publications. In addition to supervising translational research in his laboratory, he has taken on increasing administrative responsibilities, ultimately overseeing 21 laboratories responsible for target and biomarker discovery, translational research, and preclinical therapeutic development in inflammatory, autoimmune, fibrotic, and ophthalmic diseases.

Davis Liu, MD, is a board certified family doctor who joined Lemonaid Health in 2015 and serves as the chief clinical officer since 2017. Previously Dr. Liu was a practicing primary care doctor at Kaiser Permanente from 2000 to 2015, and held a variety of leadership roles including as a board member of the Permanente Medical Group as well as chief of chronic conditions management for the Roseville medical center, as well as implemented new workflows in primary care and mental health. He is a graduate of the University of Connecticut School of Medicine as well as the Wharton School of Business at the University of Pennsylvania.

Jennifer Low, M.D., Ph.D. joined 23andMe in 2018 as Head of Therapeutics Development. She oversees the transition of potential therapeutics from 23andMe's research laboratories into clinical development studies. Jennifer has considerable drug development experience and has most recently worked as a consultant and advisor to biotech CEOs and investors on their drug development strategies. She has been the Chief Medical Officer and Executive Vice President of Research and Development at Loxo Oncology where she oversaw the clinical development of Vitrakvi (Trk inhibitor). Prior to that, she was a Senior Group Director at Genentech, a member of the Roche Group, where she oversaw the Erivedge (hedgehog), Zelboraf (b-RAF), and Cotellic (mek) clinical development programs among many others. She received her undergraduate degree from Caltech, her MD and PhD degrees from Georgetown, and completed her internal medicine residency at the University of California Davis, her medical oncology fellowship at the National Cancer Institute, and was a Senior Investigator at the Cancer Therapeutics Evaluation Program at NCI and an attending physician in breast cancer at the National Institutes of Health and the National Naval Medical Center in Bethesda. She has co-authored papers appearing in the New England Journal of Medicine, Science, Cancer Discovery, Journal of Clinical Oncology, and Nature Reviews Cancer.

Steve joined 23andMe in 2018 as Chief Financial Officer, responsible for all aspects of the financial operations of the company, including accounting and controls, financial planning and analysis, tax planning and compliance, as well as funding,cash management and investor relations. Previously, Steve served as CEO of Miramax Films for five years while concurrently serving as CFO, a position he held from 2010. He led the building of a new studio company from the Miramax assets purchased from The Walt Disney Company in late 2010. During this period, Miramax built its distribution reach to 200 countries and re-launched its original content film and television development, and production and distribution capabilities. In 2016, Steve helped orchestrate the sale of Miramax to beIN Media Group. Before joining Miramax, Steve held various senior financial roles at biopharmaceutical company Amgen, Inc., including Corporate Controller and divisional CFO, helping steward annual revenue growth from $3 billion to over $15 billion in less than ten years. Prior to that, he was Executive Vice President and Chief Financial Officer at eToys, Inc., a pioneering internet retailer of children’s products, where he led the company’s IPO, with an initial $8 billion market value. Steve’s early career included a variety of financial positions in the media industry, including at The Walt Disney Company and the Times Mirror Company. Steve holds a Bachelor of Science in Civil Engineering degree from Tufts University and a Master’s of Business Administration degree from the Tuck School of Business Administration, Dartmouth College.